Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1863-1870

  Chen, Qingjuan ^a   Ge, Xiaojun ^b   Zhang, Yuchen ^b   Xia, Hongwei ^b   Yuan, Dandan ^a   Tang, Qiulin ^b   Chen, Liang ^b   Pang, Xiaohui ^a   Leng, Weibing ^a   Bi, Feng ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Distant metastasis; Gastric cancer; MiR 122; MiR 192; Plasma biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 122; MICRORNA 192; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CELL STRAIN; CELL STRAIN CTC105; CELL STRAIN CTC141; CHRONIC GASTRITIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICRORNA 122 BLOOD LEVEL; MICRORNA 192 BLOOD LEVEL; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STOMACH CANCER; STOMACH ULCER; SURVIVAL TIME; VALIDATION PROCESS;

ADULT; AGED; BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTOME;

EID: 84904757320     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3004     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20, 2006.
5. Schlansky B and Sonnenberg A: Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol 106: 1978-1985, 2011.
6. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
7. Glimelius B, Ekström K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
8. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
9. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
11. Roth AD, Fazio N, Stupp R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25: 3217-3223, 2007.
12. Chang YR, Han DS, Kong SH, et al: The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol 19: 1231-1239, 2012.
13. Li C, Yan M and Zhu ZG: Nonpalliative surgical resection for gastric cancer patients with distant metastasis. J Invest Surg 25: 100-106, 2012.
14. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
15. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
16. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
17. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
18. Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B and Hofman P: MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 16: 1047-1061, 2009.
19. Shen J, Stass SA and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329: 125-136, 2012.
20. Allegra A, Alonci A, Campo S, et al: Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (Review). Int J Oncol 41: 1897-1912, 2012.
21. Blanco-Calvo M, Calvo L, Figueroa A, Haz-Conde M, Antón-Aparicio L and Valladares-Ayerbes M: Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors 12: 9349-9362, 2012.
22. Song MY, Pan KF, Su HJ, et al: Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 7: e33608, 2012.
23. Wang M, Gu H, Wang S, et al: Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep 5: 1514-1520, 2012.
24. Chen T, Yang K, Yu J, et al: Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 22: 248-258, 2012.
25. Liu R, Zhang C, Hu Z, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784-791, 2011.
26. Hu Z, Dong J, Wang LE, et al: Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33: 828-834, 2012.
27. Takei Y, Takigahira M, Mihara K, Tarumi Y and Yanagihara K: The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 71: 1442-1453, 2011.
28. Gui J, Tian Y, Wen X, et al: Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci 120: 183-193, 2011.
29. Hurst DR, Edmonds MD and Welch DR: Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498, 2009.
30. Hur K, Toiyama Y, Takahashi M, et al: MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62: 1315-1326, 2012.
31. Valastyan S, Reinhardt F, Benaich N, et al: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046, 2009.
32. Jopling C, Norman K and Sarnow P: Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. In: Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor Laboratory Press, pp369-376, 2006.
33. Etiemble J, Möröy T, Jacquemin E, Tiollais P and Buendia M: Fused transcripts of c-myc and a new cellular locus, hcr in a primary liver tumor. Oncogene 4: 51-57, 1989.
34. Girard M, Jacquemin E, Munnich A, Lyonnet S and Henrion-Caude A: miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48: 648-656, 2008.
35. Wu X, Somlo G, Yu Y, et al: De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10: 42, 2012.
36. Iino I, Kikuchi H, Miyazaki S, et al: Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. Cancer Sci 104: 624-630, 2013.
37. Tsai WC, Hsu PWC, Lai TC, et al: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582, 2009.
38. Hsu SH, Wang B, Kota J, et al: Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122: 2871-2883, 2012.
39. Gu J, Wang Y and Wu X: MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des 19: 1292-1300, 2013.
40. Zhao C, Zhang J, Zhang S, et al: Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Oncol Rep 30: 276-284, 2013.
41. Schee K, Lorenz S, Worren MM, et al: Deep sequencing the MicroRNA transcriptome in colorectal cancer. PLoS One 8: e66165, 2013.
42. Chiang Y, Song Y, Wang Z, et al: microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 3: 560-566, 2012.
43. Wang G, Chan ES, Kwan BC, et al: Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10: 106-113, 2012.
44. Kim T, Veronese A, Pichiorri F, et al: p53 regulates epithelial- mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208: 875-883, 2011.
45. Chiang Y, Zhou X, Wang Z, et al: Expression levels of microRNA-192 and -215 in gastric carcinoma. Pathol Oncol Res 18: 585-591, 2012.